成都先导药物开发股份有限公司主营业务是DEL技术相关的药物研发服务，公司的主要服务主要包含 DEL筛选服务,DEL库定制,FBDD/SBDD,新药定制开发,化合物结构知识产权转让及化学合成等其他新药 研发相关服务等。截至报告期末，公司累计已取得138项发明专利及13项软件著作授权，并有300余项境 内外发明专利正在申请中。同时，公司在过去十余年的工作中围绕DEL技术领域进行了大量的研究和探 索性工作，从而积累了大量的技术诀窍，是其它公司和科研单位难以在短期内通过阅读文献和自身研发 而实现的。 6月9日，成都先导今日收盘17.26元，上涨2.31%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到105.26倍，总市值69.16亿元。 从行业市盈率排名来看，公司所处的医疗服务行业市盈率平均41.42倍，行业中值44.32倍，成都先导排 名第40位。 股东方面，截至2025年3月31日，成都先导股东户数16254户，较上次增加2538户，户均持股市值35.28 万元，户均持股数量2.76万股。 最新一期业绩显示，2025年一季报，公司实现营业收入1.07亿元，同比-0.60%；净利润2828.44万元 ...

Group 1 - The core viewpoint of the article highlights Chengdu Xian Dao's current stock performance, with a closing price of 15.82 yuan, an increase of 1.54%, and a rolling PE ratio of 96.48, marking a new low in 20 days, with a total market value of 6.339 billion yuan [1] - Chengdu Xian Dao ranks 40th in the medical services industry based on PE ratio, which has an average of 38.66 and a median of 38.36 [1] - As of March 31, 2025, the number of shareholders for Chengdu Xian Dao has increased to 16,254, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Group 2 - The main business of Chengdu Xian Dao includes drug early discovery and development services related to DEL technology, offering services such as DEL screening, DEL library customization, FBDD/SBDD, custom drug development, compound structure intellectual property transfer, and chemical synthesis [1] - In the latest quarterly report for Q1 2025, the company achieved an operating income of 107 million yuan, a year-on-year decrease of 0.60%, while net profit reached 28.2844 million yuan, a year-on-year increase of 102.90%, with a gross profit margin of 51.87% [1]

Group 1 - The core viewpoint of the article highlights Chengdu Xian Dao's stock performance, with a closing price of 14.88 yuan, up 5.08%, and a rolling PE ratio of 90.75, marking a new low in 17 days, with a total market value of 5.962 billion yuan [1] - Chengdu Xian Dao ranks 37th in the medical services industry, which has an average PE ratio of 40.74 and a median of 42.36 [1] - As of March 31, 2025, the number of shareholders for Chengdu Xian Dao increased to 16,254, with an average holding value of 352,800 yuan and an average holding of 27,600 shares [1] Group 2 - Chengdu Xian Dao specializes in drug discovery and development services related to DEL technology, including DEL screening services, custom DEL libraries, FBDD/SBDD, custom drug development, compound structure intellectual property transfer, and other related services [1] - In the latest quarterly report for Q1 2025, the company reported revenue of 107 million yuan, a year-on-year decrease of 0.60%, while net profit reached 28.2844 million yuan, a year-on-year increase of 102.90%, with a gross profit margin of 51.87% [1]